News articles about AbbVie (NYSE:ABBV) have been trending somewhat negative this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AbbVie earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 43.8859261196754 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Jury Backs AbbVie Payment — WSJ (ih.advfn.com)
- AbbVie Ordered To Pay $150 Mln In AndroGel Lawsuit (rttnews.com)
- Seeger Weiss LLP Reports: Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man; Awards $150 Million in Punitive Damages (nasdaq.com)
- U.S. jury finds AbbVie liable for misrepresentation in first AndroGel verdict (timesofindia.indiatimes.com)
- AbbVie Stock Is All Set for a Bullish Price Advance (profitconfidential.com)
AbbVie (NYSE ABBV) opened at 73.91 on Tuesday. The company has a market capitalization of $117.63 billion, a price-to-earnings ratio of 19.16 and a beta of 1.51. The firm has a 50 day moving average of $71.63 and a 200-day moving average of $65.94. AbbVie has a 1-year low of $55.06 and a 1-year high of $75.04. AbbVie also was the target of some unusual options trading activity on Monday. Traders purchased 278 put options on the stock. This represents an increase of approximately 121% compared to the average volume of 126 put options.
AbbVie (NYSE:ABBV) last posted its earnings results on Thursday, April 27th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.02. The business had revenue of $6.54 billion for the quarter, compared to analysts’ expectations of $6.49 billion. AbbVie had a net margin of 24.07% and a return on equity of 148.83%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.15 EPS. On average, equities research analysts anticipate that AbbVie will post $5.53 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be paid a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a yield of 3.46%. The ex-dividend date is Wednesday, July 12th. AbbVie’s dividend payout ratio is currently 66.32%.
ABBV has been the subject of a number of research analyst reports. Vetr upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 target price for the company in a research note on Monday, May 8th. Credit Suisse Group reissued a “neutral” rating and issued a $74.00 price target (up previously from $65.00) on shares of AbbVie in a report on Thursday, July 20th. BMO Capital Markets set a $63.00 price target on shares of AbbVie and gave the company a “hold” rating in a report on Thursday, April 27th. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, June 22nd. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. AbbVie has an average rating of “Buy” and a consensus target price of $74.52.
In other news, EVP Carlos Alban sold 45,800 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $70.00, for a total value of $3,206,000.00. Following the transaction, the executive vice president now owns 160,545 shares in the company, valued at approximately $11,238,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Chase sold 38,300 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the completion of the transaction, the chief financial officer now owns 209,043 shares in the company, valued at approximately $13,660,960.05. The disclosure for this sale can be found here. Insiders have sold a total of 278,135 shares of company stock worth $18,841,085 in the last 90 days. Company insiders own 0.23% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
